<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00839150</url>
  </required_header>
  <id_info>
    <org_study_id>P041009</org_study_id>
    <nct_id>NCT00839150</nct_id>
  </id_info>
  <brief_title>Retinal Function in Diabetic Patients Without Retinopathy</brief_title>
  <acronym>NEURODIAB</acronym>
  <official_title>Assessment of Retinal Functional Abnormalities in Diabetic Patients Without Retinopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose was to assess, in diabetic patients without diabetic retinopathy and&#xD;
      control subjects, color vision, contrast sensitivity, electroretinography, and&#xD;
      flicker-induced vasodilatation using the Dynamic Vessel Analyzer, in order to specify the&#xD;
      earliest impaired retinal cells in diabetes, and gain more insight into diabetic retinopathy&#xD;
      pathogenesis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type 1 and type 2 diabetic patients with no diabetic retinopathy and no hypertension were&#xD;
      compared with sex and age-matched control subjects. Color vision was tested with the&#xD;
      desaturated LANTHONY 15-Hue test. Contrast sensitivity was assessed with the Pelli-Robson&#xD;
      contrast sensitivity test. Pattern-electroretinogram, Ganzfeld full-field electroretinogram&#xD;
      and multifocal electroretinogram were recorded according to the International Society for&#xD;
      Clinical Electrophysiology of Vision (ISCEV). Flicker-induced vasodilatation in retinal&#xD;
      arteries and veins was assessed using the Dynamic Vessel Analyzer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">56</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Diabetic patients without diabetic retinopathy : No intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Sex and age-matched control subjects : No intervention</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        For diabetic patients :&#xD;
&#xD;
        age between 20 and 55 type 1 or type 2 diabetes mellitus diabetes duration of more than 5&#xD;
        years no diabetic retinopathy on fundus examination or fundus photographs&#xD;
&#xD;
        For control subjects :&#xD;
&#xD;
        sex and age matching with the diabetic patients no diabetes, no familial or personal&#xD;
        history of elevated blood sugar&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  For diabetic patients :&#xD;
&#xD;
               -  age between 20 and 55&#xD;
&#xD;
               -  type 1 or type 2 diabetes mellitus&#xD;
&#xD;
               -  diabetes duration of more than 5 years&#xD;
&#xD;
               -  no diabetic retinopathy on fundus examination or fundus photographs&#xD;
&#xD;
          -  For control subjects :&#xD;
&#xD;
               -  sex and age matching with the diabetic patients&#xD;
&#xD;
               -  no diabetes, no familial or personal history of elevated blood sugar&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        *For both diabetic patients and control subjects :&#xD;
&#xD;
          -  presence of cataract or history of cataract surgery&#xD;
&#xD;
          -  intraocular pressure of more than 21 mmHg&#xD;
&#xD;
          -  abnormal score on the Ishihara test&#xD;
&#xD;
          -  other ocular disease&#xD;
&#xD;
          -  ametropia more than 3 diopters, anisometropia more than 1 diopter, astigmatism more&#xD;
             than 1 diopter&#xD;
&#xD;
          -  systemic hypertension (defined as systolic blood pressure &gt; 140 mmHg, diastolic blood&#xD;
             pressure &gt; 90 mmHg)&#xD;
&#xD;
          -  treatment with vasoactive drugs&#xD;
&#xD;
          -  tobacco consumption of more than 20 cigarettes a day&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pascale Massin, MD,Pr;PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital Lariboisiere</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <study_first_submitted>February 6, 2009</study_first_submitted>
  <study_first_submitted_qc>February 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2009</study_first_posted>
  <last_update_submitted>September 16, 2011</last_update_submitted>
  <last_update_submitted_qc>September 16, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic retinopathy</keyword>
  <keyword>Color vision</keyword>
  <keyword>Contrast sensitivity</keyword>
  <keyword>Electroretinogram</keyword>
  <keyword>Flicker-induced vasodilatation</keyword>
  <keyword>Dynamic Vessel Analyzer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

